Patty Taddei-Allen, PharmD, MBA, examines how co-pay accumulators, maximizers, and AFPs shift costs, impact rebates, and create access challenges for patients.
Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP
Advertisement
Articles by Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP
Rising Specialty Drug Costs and Co-Pay Models Raise Access Concerns: Patty Taddei-Allen, PharmD, MBA
Patty Taddei-Allen, PharmD, MBA, warns that co-pay accumulators and maximizers may lower plan costs but increase patient burden and disrupt medication adherence.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
3
PBM Satisfaction Stalls as Net Promoter Score Turns Negative
4
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
5